SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy
BiotechTV - News
00:00
Next steps for the ataxia program
Vlad outlines ongoing engagement with FDA and says Biohaven will focus on advancing the program or alternative portfolio options in 2026.
Play episode from 04:14
Transcript
